Details for Patent: 12,048,698

Which drugs does patent 12,048,698 protect, and when does it expire?

Patent 12,048,698 protects TUKYSA and is included in one NDA.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: 12,048,698

Title:	Treatment of HER2 positive cancers
Abstract:	In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.
Inventor(s):	Scott Peterson, Luke Walker
Assignee:	Cascadian Therapeutics Inc , Seagen Inc
Application Number:	US18/139,653
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 12,048,698

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No	12,048,698					COMBINATION TREATMENT WITH TUCATINIB AND TRASTUZUMAB OF ADULTS WITH RAS WILD-TYPE HER2-POSITIVE UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING PREVIOUS TREATMENT AS CLAIMED
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-002	Apr 17, 2020		RX	Yes	Yes	12,048,698					COMBINATION TREATMENT WITH TUCATINIB AND TRASTUZUMAB OF ADULTS WITH RAS WILD-TYPE HER2-POSITIVE UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING PREVIOUS TREATMENT AS CLAIMED

International Family Members for US Patent 12,048,698

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018258663
Australia	2022241509
Brazil	112019022280
Canada	3060407
China	111032082